The results of the present study suggest that downregulation of JMJD2B–PPARγ2 signaling might attenuate hepatic steatosis, so compounds that inhibit JMJD2B–PPARγ2 signaling can be notable therapeutic resources against this disease. This evidence concerns the gene KDM4B and Hepatic steatosis.